✦ LIBER ✦

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

✍ Scribed by Josh J. Carlson; Louis P. Garrison; Scott D. Ramsey; David L. Veenstra

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activating and resistance mutations of E

✍ Gazdar, A F 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 213 KB

EGFR tyrosine kinase inhibitors in non-s

✍ Raffaele Califano; Fiona H. Blackhall; Giovanna Finocchiaro; Luca Toschi; Nichol 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 253 KB

Epidermal growth factor receptor (EGFR)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

Quantifying the sensitivities of EGF rec

✍ Gargi Ghosh; Xiaoliang Yan; Andrew G. Lee; Stephen J. Kron; Sean P. Palecek 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 748 KB

Overview of molecular testing in non-sma

✍ John, T; Liu, G; Tsao, M-S 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 293 KB